Impact of adding the multikinase inhibitor sorafenib to endocrine therapy in metastatic estrogen receptor-positive breast cancer.
Future Oncol
; 10(15): 2435-48, 2014 Dec.
Article
en En
| MEDLINE
| ID: mdl-24826798
ABSTRACT
BACKGROUND:
Targeting growth factor and survival pathways may delay endocrine-resistance in estrogen receptor-positive breast cancer. MATERIALS &METHODS:
A pilot Phase II study adding sorafenib to endocrine therapy in 11 patients with metastatic estrogen receptor-positive breast cancer was conducted. Primary end point was response by RECIST after 3 months of sorafenib. Secondary end points included safety, time to progression and biomarker modulation. The study closed early owing to slow accrual.RESULTS:
Eight out of 11 patients had progressive disease on study entry and three had stable disease. Of the ten evaluable patients, seven experienced stable disease (70%) and three experienced progressive diseas (30%), with a median time to progression of 6.1 months (8.4 months in the seven patients on tamoxifen). The serum samples demonstrated a significant reduction in VEGF receptor 2 and PDGF receptor-α. Microarray analysis identified 32 suppressed genes, no induced genes and 29 enriched Kyoto Encyclopedia of Genes and Genomes pathways.CONCLUSION:
The strategy of adding a targeted agent to endocrine therapy upon resistance may be worthwhile testing in larger studies.Palabras clave
Texto completo:
1
Base de datos:
MEDLINE
Asunto principal:
Compuestos de Fenilurea
/
Neoplasias Óseas
/
Neoplasias Encefálicas
/
Neoplasias de la Mama
/
Niacinamida
/
Antineoplásicos Hormonales
Tipo de estudio:
Prognostic_studies
Límite:
Adult
/
Aged
/
Female
/
Humans
/
Middle aged
Idioma:
En
Revista:
Future Oncol
Año:
2014
Tipo del documento:
Article
País de afiliación:
Estados Unidos